Aprea Therapeutics announced significant recent expansions to its global intellectual property portfolio supporting its DNA Damage Response (DDR) oncology pipeline. In 2025, new patents were granted in Australia and Japan, strengthening coverage for its WEE1 and ATR programs. The core patent families are expected to provide exclusivity into 2045, with additional pending applications that could further extend protection. The WEE1 portfolio protects new chemical entities, pharmaceutical compositions, and methods of treating oncology indications, while the ATR program is supported by multiple issued patents and pending applications internationally. Aprea also filed provisional applications in the U.S. in 2025 for macrocyclic DDR target inhibitors and their methods of use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2275224_en), on February 12, 2026, and is solely responsible for the information contained therein.